217 related articles for article (PubMed ID: 23137582)
1. Safe use of antirheumatic agents in patients with comorbidities.
Makol A; Wright K; Matteson EL
Rheum Dis Clin North Am; 2012 Nov; 38(4):771-93. PubMed ID: 23137582
[TBL] [Abstract][Full Text] [Related]
2. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study.
van Halm VP; Nurmohamed MT; Twisk JW; Dijkmans BA; Voskuyl AE
Arthritis Res Ther; 2006; 8(5):R151. PubMed ID: 16984661
[TBL] [Abstract][Full Text] [Related]
3. The safety of anakinra in high-risk patients with active rheumatoid arthritis: six-month observations of patients with comorbid conditions.
Schiff MH; DiVittorio G; Tesser J; Fleischmann R; Schechtman J; Hartman S; Liu T; Solinger AM
Arthritis Rheum; 2004 Jun; 50(6):1752-60. PubMed ID: 15188350
[TBL] [Abstract][Full Text] [Related]
4. Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis.
Solomon DH; Avorn J; Katz JN; Weinblatt ME; Setoguchi S; Levin R; Schneeweiss S
Arthritis Rheum; 2006 Dec; 54(12):3790-8. PubMed ID: 17136752
[TBL] [Abstract][Full Text] [Related]
5. Co-morbidities in established rheumatoid arthritis.
Gullick NJ; Scott DL
Best Pract Res Clin Rheumatol; 2011 Aug; 25(4):469-83. PubMed ID: 22137918
[TBL] [Abstract][Full Text] [Related]
6. Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis.
Lacaille D; Guh DP; Abrahamowicz M; Anis AH; Esdaile JM
Arthritis Rheum; 2008 Aug; 59(8):1074-81. PubMed ID: 18668604
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular risk in rheumatoid arthritis.
Nurmohamed MT
Autoimmun Rev; 2009 Jul; 8(8):663-7. PubMed ID: 19393192
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for cardiovascular disease in rheumatoid arthritis.
Gabriel SE; Crowson CS
Curr Opin Rheumatol; 2012 Mar; 24(2):171-6. PubMed ID: 22249350
[TBL] [Abstract][Full Text] [Related]
9. Comorbidities in rheumatoid arthritis.
Michaud K; Wolfe F
Best Pract Res Clin Rheumatol; 2007 Oct; 21(5):885-906. PubMed ID: 17870034
[TBL] [Abstract][Full Text] [Related]
10. Patient, disease, and therapy-related factors that influence discontinuation of disease-modifying antirheumatic drugs: a population-based incidence cohort of patients with rheumatoid arthritis.
Maradit-Kremers H; Nicola PJ; Crowson CS; O'Fallon WM; Gabriel SE
J Rheumatol; 2006 Feb; 33(2):248-55. PubMed ID: 16358365
[TBL] [Abstract][Full Text] [Related]
11. [Rheumatoid arthritis: a cardiovascular disease?].
Daïen CI; Fesler P
Ann Cardiol Angeiol (Paris); 2012 Apr; 61(2):111-7. PubMed ID: 21885031
[TBL] [Abstract][Full Text] [Related]
12. [Comorbidity in rheumatoid arthritis].
Albrecht K
Dtsch Med Wochenschr; 2014 Sep; 139(37):1844-8. PubMed ID: 25181002
[TBL] [Abstract][Full Text] [Related]
13. Disease-modifying antirheumatic drugs other than methotrexate in rheumatoid arthritis and seronegative arthritis.
Nandi P; Kingsley GH; Scott DL
Curr Opin Rheumatol; 2008 May; 20(3):251-6. PubMed ID: 18388514
[TBL] [Abstract][Full Text] [Related]
14. Perioperative drug safety in patients with rheumatoid arthritis.
Goodman SM; Paget S
Rheum Dis Clin North Am; 2012 Nov; 38(4):747-59. PubMed ID: 23137580
[TBL] [Abstract][Full Text] [Related]
15. Inflammatory arthritis as a novel risk factor for cardiovascular disease.
John H; Kitas G
Eur J Intern Med; 2012 Oct; 23(7):575-9. PubMed ID: 22841864
[TBL] [Abstract][Full Text] [Related]
16. Comorbidity in rheumatoid arthritis.
Turesson C
Swiss Med Wkly; 2016; 146():w14290. PubMed ID: 27045333
[TBL] [Abstract][Full Text] [Related]
17. Malignancy risks with biologic therapies.
Cush JJ; Dao KH
Rheum Dis Clin North Am; 2012 Nov; 38(4):761-70. PubMed ID: 23137581
[TBL] [Abstract][Full Text] [Related]
18. [Combination therapy of disease-modifying antirheumatic drugs(DMARDs) in rheumatoid arthritis].
Kobayashi S; Kanai Y
Nihon Rinsho; 2002 Dec; 60(12):2351-6. PubMed ID: 12510361
[TBL] [Abstract][Full Text] [Related]
19. Management of established rheumatoid arthritis with an emphasis on pharmacotherapy.
Blom M; van Riel PL
Best Pract Res Clin Rheumatol; 2007 Feb; 21(1):43-57. PubMed ID: 17350543
[TBL] [Abstract][Full Text] [Related]
20. Lipid profiles in patients with rheumatoid arthritis: mechanisms and the impact of treatment.
Steiner G; Urowitz MB
Semin Arthritis Rheum; 2009 Apr; 38(5):372-81. PubMed ID: 18395771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
